Stemtech (STEK) Other Non-Current Liabilities (2021 - 2022)
Stemtech's (STEK) quarterly Other Non-Current Liabilities came in at $3.4 million in Q3 2022, down 13.54% year-on-year from $4.0 million in Q3 2021, and down 87.57% quarter-over-quarter from $27.6 million in Q2 2022.
Stemtech (STEK) Other Non-Current Liabilities (2021 - 2022) Analysis & Trends
Stemtech has disclosed Other Non-Current Liabilities across 2 years of filings, most recently posting $3.4 million for Q3 2022.
- Other Non-Current Liabilities for Q3 2022 came in at $3.4 million, down 13.54% year-over-year; the trailing twelve-month figure through Sep 2022 was $3.4 million (down 13.54% YoY), and the FY2021 annual result was $4.2 million, changed N/A from the prior year.
- Other Non-Current Liabilities came in at $3.4 million for Q3 2022 at Stemtech, down from $27.6 million in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $27.6 million in Q2 2022 to a low of $3.4 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn |
| 10 | Stemtech | - | - | 354,677.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 3.43 Mn |
| Jun 30, 2022 | 27.61 Mn |
| Mar 31, 2022 | 4.03 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | 3.97 Mn |